Bouma B N, Kerbiriou D M, Baker J, Griffin J H
J Clin Invest. 1986 Jul;78(1):170-6. doi: 10.1172/JCI112547.
Studies of plasma prekallikrein in a family with prekallikrein deficiency were made. Three children had no clotting activity but approximately 35% antigen levels, and the mother and five children had twice as much prekallikrein antigen as clotting activity, suggesting the presence of a dysfunctional molecule. A nonfunctional variant form of prekallikrein was purified that contained no prekallikrein clotting activity. The variant and normal molecules were both 80,000 mol wt, immunologically indistinguishable and complexed similarly with high molecular weight kininogen. Isoelectric focusing studies suggested a difference of one charged amino acid residue. The variant was cleaved by beta-Factor XIIa 200 times slower than the normal molecule, and no amidolytic activity was detected for the cleaved variant. These data and other observations suggest that an amino acid was substituted in the variant near the NH2-terminal end of the kallikrein light chain resulting in slower cleavage by beta-Factor XIIa and the absence of enzymatic activity.
对一个患有前激肽释放酶缺乏症的家族进行了血浆前激肽释放酶的研究。三个孩子没有凝血活性,但抗原水平约为35%,母亲和五个孩子的前激肽释放酶抗原量是凝血活性的两倍,提示存在功能异常的分子。纯化出一种无功能的前激肽释放酶变异体形式,其不具备前激肽释放酶凝血活性。变异体和正常分子的分子量均为80,000,免疫上无法区分,且与高分子量激肽原的结合方式相似。等电聚焦研究提示有一个带电荷的氨基酸残基存在差异。变异体被β-因子XIIa切割的速度比正常分子慢200倍,且切割后的变异体未检测到酰胺水解活性。这些数据和其他观察结果表明,在激肽释放酶轻链NH2末端附近的变异体中一个氨基酸被取代,导致被β-因子XIIa切割变慢且缺乏酶活性。